Aerocrine Announces Presentation of Data on FeNO Testing in Overlap Syndrome
News May 21, 2013
Aerocrine, Inc. announced the following scientific abstract, Characterization of Allergic Airway Inflammation in Patients with COPD using Fractional exhaled Nitric Oxide Level (FeNO)s, presented at the 2013 American Thoracic Society International Conference. The abstract was presented by Dr. James F. Donohue, principle investigator for the study at (American Thoracic Society meeting in Philadelphia) on (Sunday May 19, 2013).
Asthma can coexist with chronic obstructive pulmonary disease (COPD), particularly in older adults, a condition labeled overlap syndrome. While airway inflammation in COPD is largely neutrophilic, some patients with COPD may have features of asthma and thus may also have a component of allergic airway inflammation
The single-visit, outpatient study was conducted in 97 subjects age 40 and older with COPD or overlap syndrome. All subjects performed spirometry and fractional exhaled nitric oxide (FeNO) measurements were taken with Aerocrine’s NIOXMINO® device. COPD severity was classified according to guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Conclusions of the study were as follows:
• Increases in FeNO do occur in patients with COPD. In addition, approximately 11% of patients demonstrated increases in FeNO to intermediate or high levels.
• FeNO is useful for identifying patients with allergic airway inflammation who will have a beneficial response to treatment with an inhaled corticosteroid. The resulting data may have important implications for the management of COPD patients who may have Overlap Syndrome.
“Fractional exhaled nitric oxide is proving to be a valuable biomarker,” says Scott Myers, president and CEO of Aerocrine AB. “Pulmonologists are learning how they can help direct treatment for asthma patients, but with this additional clinical research we are demonstrating that because of overlap disease it can also help for care of their patients with COPD who may have an asthma component (Overlap Syndrome).
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Microbiotica Enters into Microbiome Collaboration with GenentechNews
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline.READ MORE